Aciphex is a prescription medication that contains rabeprazole as its active ingredient. It belongs to the digestive health therapeutic class and is formulated as an oral pill. In Hong Kong, Aciphex is regulated by the Department of Health and is available in two strengths: 10 mg and 20 mg tablets.
Rabeprazole works as a proton-pump inhibitor (PPI) to reduce stomach acid production, which helps manage several acid-related gastrointestinal conditions.
Rabeprazole belongs to the class of proton-pump inhibitors. It selectively and irreversibly blocks the H⁺/K⁺-ATPase enzyme (the “proton pump”) located in the parietal cells of the stomach lining. By inhibiting this final step of gastric acid secretion, rabeprazole lowers both basal and stimulated acid output.
Because rabeprazole is absorbed systemically before acting on the gastric wall, it has a high bioavailability (≈ 52 % after oral administration). It is metabolised primarily by the liver enzyme CYP2C19, with a smaller contribution from CYP3A4.
Aciphex is approved in Hong Kong for the following indications:
These uses reflect the drug’s ability to maintain a higher gastric pH, allowing damaged mucosa to heal and reducing symptoms such as heartburn and epigastric pain.
If any of these conditions apply, a healthcare professional should evaluate the risk-benefit balance before initiating therapy.
These effects are typically self-limiting and do not require medical intervention unless they persist.
These events are rare but warrant prompt evaluation.
Patients should disclose all prescription medications, over-the-counter drugs, and herbal supplements before starting Aciphex.
Standard adult dosing:
GERD, erosive oesophagitis, or ulcer healing: 20 mg once daily for 4-8 weeks, depending on the indication.
Prevention of NSAID-induced ulcers: 20 mg once daily taken concurrently with the NSAID.
Zollinger-Ellison syndrome: 20 mg twice daily (morning and evening) may be required; dosing is individualized based on acid output.
Dose adjustments:
Renal impairment: no dose modification is needed for mild to moderate renal dysfunction; severe impairment should be approached cautiously.
Hepatic impairment: consider reducing the dose to 10 mg once daily for patients with severe liver disease (Child-Pugh C).
Administration tips: swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet, as this may affect the drug’s release profile.
Missed dose: if a dose is forgotten, take it as soon as remembered unless it is close to the time of the next scheduled dose; do not double-dose.
Overdose: symptoms may include severe drowsiness, confusion, or fainting. Seek emergency medical care; supportive measures are the mainstay of treatment.
Discontinuation: abrupt cessation is generally safe, but patients who have been on high-dose PPIs for prolonged periods should discuss tapering with a clinician to minimise rebound acid hypersecretion.
Regular follow-up ensures optimal therapeutic outcomes while mitigating potential risks.
This article provides educational information about Aciphex and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Aciphex may be taken with or without food, and the time of day does not significantly affect its efficacy. Maintaining a consistent daily schedule helps achieve stable acid control.
Persistent diarrhoea could signal a serious infection such as Clostridioides difficile. Seek medical evaluation promptly to determine whether further investigation or treatment is required.
Rabeprazole can affect the metabolism of warfarin through CYP2C19 inhibition, potentially altering INR levels. Regular monitoring of coagulation parameters is advisable when both drugs are used concomitantly.
Most duodenal ulcers show significant healing within 4 weeks of consistent 20 mg daily dosing, though the exact duration depends on ulcer size, patient health, and adherence.
Long-term suppression of stomach acid may impair absorption of vitamin B₁₂ and magnesium. Periodic laboratory testing is recommended for patients on extended therapy.
Older adults may be more susceptible to fractures and electrolyte imbalances with prolonged PPI use. Dose minimisation and periodic review of necessity are prudent strategies.
No specific foods must be avoided, but consuming highly acidic or spicy foods may still provoke symptoms in some individuals despite acid suppression.
Yes, Aciphex has been evaluated and approved by the Hong Kong Department of Health for the indications listed above.
The two strengths allow clinicians to tailor the dose to the severity of the condition and patient response. Typically, 20 mg is used for most adult indications, while 10 mg may be sufficient for maintenance or for patients requiring lower exposure.
Herbal products that affect gastric pH (e.g., antacids derived from calcium carbonate) or those metabolised by CYP2C19 (e.g., St. John’s wort) could theoretically alter rabeprazole’s effectiveness. Discuss all supplements with a healthcare professional before starting therapy.
